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Immune checkpoint inhibitors (ICI) have become part 
of the standard of care of patients with locally advanced 
and advanced non-small cell lung cancer (NSCLC) (1). 
Corticosteroids are broadly used as premedication for 
most chemotherapy regimens and are frequently used to 
alleviate pain or dyspnea, to stimulate appetite, or to palliate 
symptoms associated with brain or epidural metastases. 
However, corticosteroids have anti-inflammatory and 
immunosuppressive effects that act over both innate and 
adaptive immunity. Based on this, patients treated with 
corticosteroids at doses equal to or higher than 10 mg/day 
of prednisone or equivalent have been systematically 
excluded from clinical trials of ICI.
Corticosteroids are characterized by their pleiotropic 
effect on multiple signaling pathways, including the 
modulation of the immune system. In cancer, glucocorticoids 
have an impact along all immune-cycle canonical steps: from 
the release of cancer cell antigens to lymphocyte trafficking 
within the tumor as well as in the effector phase of tumor 
destruction (2). Corticosteroids suppress the initial activation 
of inflammatory pathways that are involved in the detection 
of noxious agents, such as toll-like receptor (TLR) signaling 
and the NF-κB pathway. Corticosteroids reduce eicosanoid 
and prostaglandin production and inhibit the expression of 
pro-inflammatory cytokines like IL-1α, IL-1β, IL-2, IL-6, 
IL-12, interferon-γ (IFN-γ), tumor necrosis factor (TNF), 
and granulocyte-macrophage colony-stimulating factor 
(GM CSF). Moreover, glucocorticoids reduce lymphocyte 
extravasation by inhibiting endothelial expression of 
E-selectin and integrin ligands [vascular cell adhesion 
molecule 1 (VCAM-1); intercellular adhesion molecule 1 
(ICAM-1)] and decrease the secretion of chemoattractants 
and chemokines (CXCL8 and CCL2), and leucocyte 
adhesion molecules (CD44 and integrins) in the tumor 
microenvironment. Finally, corticosteroids impair activation 
of T lymphocytes, by blocking T helper 1 and recruiting 
T regulatory cells and can also induce M2 macrophages 
polarization.
Corticosteroids also lead to changes in the peripheral 
blood immune cells. In a recent study, Fucà et al. showed 
that early use of steroids was significantly correlated with 
higher median absolute neutrophil count, neutrophil to 
lymphocyte ratio (NLR), and derived NLR (dNLR) with a 
lower median absolute and relative eosinophil count (REC) 
after ICI treatment (3). A high NLR/dNLR and a low 
REC at 4 and 6 weeks after treatment were associated with 
reduced benefit from ICI treatment suggesting that early 
use of steroids may worsen patient outcome by modulating 
peripheral white blood cells.
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Oncology, Arbour et al., retrospectively evaluated the impact 
of baseline steroids on the efficacy of programmed cell 
death-1 and programmed death-ligand 1 [PD-(L)1] blockade 
in patients with NSCLC (4). As corticosteroids are often 
used in patients with NSCLC to control tumor-related 
symptoms or chronic obstructive pulmonary disease (COPD) 
exacerbations, it is highly clinically relevant in this setting 
to know whether concomitant use of corticosteroids may 
have a detrimental effect. This study included 640 patients 
with NSCLC treated with single PD-(L)1 blockade from 
Memorial Sloan Kettering Cancer Center (MSKCC) and 
Institute Gustave Roussy (IGR). Ninety patients (14%) were 
treated with baseline steroids ≥10 mg/day at the initiation of 
PDL-(L)1 blockade (53 patients in the MSKCC cohort and 
37 in the IGR cohort). The clinicopathologic characteristics 
were well balanced between patients who received or did 
not receive corticosteroids, with the exception of history of 
brain metastases and poor Eastern Cooperative Oncology 
Group (ECOG) performance status (PS), which were more 
common in the group receiving corticosteroids at baseline. 
In both cohorts, patients receiving steroids at baseline had 
statistically shorter median progression-free survival (PFS) 
(1.9 versus 2.6 months in the MSKCC cohort, P<0.001 and 
1.7 versus 1.8 months for the IGR cohort, P<0.001) and 
shorter median overall survival (OS) (5.4 versus 12.1 months 
for the MSKCC cohort, P<0.001 and 3.3 versus 9.4 months 
for the IGR cohort, P<0.001). In the multivariate analysis of 
the pooled cohort of MSKCC and IGR the use of baseline 
corticosteroids at >10 mg/day of prednisone or equivalent 
was independently associated with worse PFS and OS, after 
adjusting for smoking history, ECOG PS, and history of 
brain metastases. 
The authors also analyzed the effect of different 
corticosteroid doses and observed that the detrimental 
effect was similar in patients treated with 10–19 mg/day or 
>20 mg/day of prednisone compared with patients not 
treated with corticosteroids. In the MSKCC cohort, the use 
of corticosteroids within 30 days before starting anti-PD-
(L)1 treatment was also collected. Interestingly, patients 
who were receiving corticosteroids within 30 days of 
initiating treatment with anti-PD-(L)1 but discontinued 
at some point before receiving the first dose had an 
intermediate survival outcome compared with patients who 
did not receive any corticosteroids at all. Nevertheless, 
specific information on the length of steroid use or days 
from steroid discontinuation to ICI initiation is lacking. 
The retrospective design of the study and the relatively 
small number of patients included in the corticosteroid 
subgroup are major limitations of the study. Indeed, as 
patients receiving corticosteroids are more likely to have 
unfavorable prognostic factors, such as poor ECOG 
PS, brain metastases, high tumor burden, or significant 
comorbidities, it is difficult to distinguish the potential 
negative impact of steroids from the intrinsic poor prognosis 
of the individuals who require steroids. Another limitation 
of the study is that patients were not stratified according to 
the indication for corticosteroids, probably due to the small 
number of patients. Different reasons for using steroids 
may have an impact on prognosis, especially if patients are 
taking steroids to overcome comorbidity exacerbations or to 
alleviate cancer-related symptoms. 
Two additional studies have also reported an unfavorable 
effect of corticosteroids in patients with advanced NSCLC 
treated with ICI, and are summarized in Table 1 (3,5). In 
both studies, use of corticosteroids at baseline or at ICI 
initiation consistently correlated with worse outcome in 
terms of PFS and OS. However, there were differences 
in the study population and in the time period to assess 
corticosteroid use. In both studies, the multivariate analysis 
showed a detrimental effect of corticosteroids independently 
of other clinical covariates (ECOG PS, age, presence of 
brain metastases). 
Strikingly, when corticosteroids or other immunomodulating 
agents, such as anti-TNF therapy, have been used to treat 
immune related adverse events (irAEs) associated with 
ipilimumab treatment in patients with melanoma there 
was not an unfavorable effect on OS or time to treatment 
failure (6). In this sense, the impact of corticosteroids used 
to manage irAEs on the clinical outcome of patients with 
advanced NSCLC was assessed in two post-hoc analyses 
from the KEYNOTE-001 and OAK clinical trials (7,8). 
Both analyses showed that patients with NSCLC receiving 
corticosteroids to manage irAEs did not experience worse 
overall response rate, PFS or OS. Since the number of 
patients receiving corticosteroids was small (n=28 in the 
KEYNOTE-001 and n=24 in the OAK trial), confirmation 
of these observations is warranted in prospective studies.
Information regarding CTLA-4 blockade and use of 
corticosteroids is scarce in NSCLC patients. Although using 
corticosteroids for the management of irAEs due to CTLA-
4 blockade has not been shown to have a detrimental effect 
in treatment efficacy (6), the impact of baseline high-dose 
corticosteroids prior to CTLA-4 blockade has not been 
investigated in the clinic. Preclinical data suggest that 
corticosteroids may have implications on CTLA-4 blocking 
antibodies like ipilimumab. Dexamethasone blocks naïve 
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T-cell proliferation and differentiation by attenuating CD28 
co-stimulation, while upregulating CTLA-4 expression in 
CD4+ and CD8+ T cells. CTLA-4 blockade can partially 
rescue T cells from the immunosuppressive effects of 
dexamethasone (9). CTLA-4, but not PD(L)-1 blockade can 
partially prevent the inhibitory effects of dexamethasone on 
the immune response.
Clinical trials assessing the combination of PD-(L)1 
blockade plus chemotherapy as first-line treatment for 
advanced NSCLC also excluded patients who were receiving 
corticosteroids at the time of randomization. However, 
corticosteroids are also part of most chemotherapy regimens 
and most phase III chemotherapy-ICI combination clinical 
trials in the first line setting have been positive (10-12). In this 
regard, a post-hoc analysis conducted in the KEYNOTE-407 
study showed similar efficacy results for patients receiving 
the nab-paclitaxel regimen, which allows to reduce the dose 
of corticosteroids, compared with patients who received 
the paclitaxel regimen (13). These results suggest that short 
courses of corticosteroids might have a small impact on the 
immune function and clinical outcome.
In conclusion, the work of Arbour et al. is relevant 
because use of high dose corticosteroids at baseline or 
shortly after starting single PD-(L)1 blockade appears to 
have a negative impact on clinical outcome in patients with 
advanced NSCLC (4). However, the results from current 
retrospective studies do not allow to discern whether 
corticosteroids have unfavorable predictive value for ICI 
blockade or are just reflecting a subgroup of poor-risk 
patients with dismal prognosis. In other words, it is difficult 
to know whether corticosteroid use is a prognostic factor 
rather than a predictive factor of poor outcome. To address 
this issue, longitudinal studies should be conducted to 
prospectively collect the timing and dosing (pre- and post-
ICI) of corticosteroids and their indication, as well as to 
characterize patient comorbidities by using validated scales 
like the Charlson comorbidity index, simplified comorbidity 
score, or cumulative illness rating scale (CIRS) (14-16). For 
now, caution is recommended when using corticosteroids 
prior to PD-(L)1 blockade, since they can impair the ability 
of the immune system to attack tumor cells and may lessen 
the efficacy of immunotherapy. 
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